Celltrion nabs EU approval of first subcutaneous infliximab biosimilar
South Korea’s Celltrion Healthcare (Kosdaq: 068270) today announced that the European Commission has approved Remsima SC (CT-P13 SC, biosimilar infliximab) for patients with rheumatoid arthritis (RA).
Remsima SC is the world’s first subcutaneous formulation of infliximab, which is marketed as Remicade by Johnson & Johnson (NYSE: JNJ) subsidiary Janssen. Remsima SC will launch in major markets such as Germany, the UK and the Netherlands in the first quarter of 2020, estimated to be worth $4 billion. By the fourth quarter, the domination rate is expected to reach 89%, worth $7.9 billion, according to Celltrion’s projections.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze